COVID-19

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV…

2 years ago

Advanced Health Intelligence Signs Letter of Intent to Develop and Deploy a Digital Underwriting Solution For the Insurance Industry

Highlights AHI signs a letter of Intent with Unisure.SCOR (SCR.FP) and Unisure to collaborate with AHI.SCOR is one of the…

2 years ago

Red Light Holland: Mistercap’s Launches Organic Grow-Your-Own Mushroom Kits for Sale at www.Mistercap.com

Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light…

2 years ago

Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer

- Research study demonstrates regulation of chromatin structure and cancer gene expression – - Findings to augment clinical trial in…

2 years ago

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

2 years ago

Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal

Important step in continued protection of Poolbeg's patent familyLONDON, UK / ACCESSWIRE / September 19, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)…

2 years ago

TNDM INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tandem Diabetes Care, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Tandem Diabetes Care, Inc. (NASDAQ: TNDM)…

2 years ago

Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2023) - Biocure Technology Inc. (CSE: CURE) ("CURE" or the "Company") announces that…

2 years ago

Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Interventional study compares VitaGraft to current transplant rejection monitoring protocolsOncocyte's VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than…

2 years ago